All Issue

2026 Vol.56, Issue 2 Preview Page

Review Article

The Neutrophil Paradox in Nontuberculous Mycobacterial Infections
Jin Kyung Kim1
,
Sang Min Jeon234
,
Asmita Sapkota234
,
Young Jae Kim234
,
Eun-Kyeong Jo235*
1Department of Microbiology, School of Medicine, Keimyung University, Daegu 42601, Republic of Korea
2Department of Microbiology, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea
3Department of Medical Science, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea
4Infection Control Convergence Research Center, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea
5Biomedical Research Institute, Chungnam National University Hospital, Daejeon 35015, Republic of Korea
*hayoungj@cnu.ac.kr
10 August 2026. pp. 112-126
PDF XML Citation
Abstract

Nontuberculous mycobacterial pulmonary disease (NTM-PD) is emerging as a global health threat and is challenging to treat because of its intrinsic resistance to multiple antibiotics. Neutrophils are the most abundant myeloid cells and serve as the principal cell type in the host’s innate immune response during infection. To date, neutrophil functions in NTM-PD have not been as extensively studied as those in tuberculosis. However, accumulating evidence suggests that neutrophils play a dual role: providing critical antimicrobial host defense, particularly during the early phase, while simultaneously contributing to pathological damage that promotes tissue destruction and structural abnormalities, such as bronchiectasis. This review provides a comprehensive overview of the paradoxical role of neutrophils in controlling innate immune defense and immunopathology during NTM infection. Further, we focused on the mechanism by which neutrophil extracellular traps serve as critical drivers of NTM pathogenesis. Furthermore, we examined the neutrophil profiles across various clinical stages in patients with NTM-PD, although the underlying mechanisms and clinical implications of these profiles remain to be fully elucidated. A deeper understanding of the precise mechanisms required to maintain the immunological balance between effective host immune defense and the prevention of pathological damage will pave the way for innovative therapeutic approaches to control NTM infections.

Keywords
Neutrophil
Nontuberculous mycobacteria
Innate immune defense
Immunopathology
Pulmonary infection
References
1

Porvaznik I, Solovic I, Mokry J. Non-Tuberculous Mycobacteria: Classification, Diagnostics, and Therapy. Adv Exp Med Biol. 2017;944:19-25.

10.1007/5584_2016_45
2

Suresh P, Kumar A, Biswas R, Vijayakumar D, Thulasidharan S, Anjaneyan G, et al. Epidemiology of Nontuberculous Mycobacterial Infection in Tuberculosis Suspects. Am J Trop Med Hyg. 2021;105(5):1335-1338.

10.4269/ajtmh.21-009534424857PMC8592207
3

Johnson MM, Odell JA. Nontuberculous mycobacterial pulmonary infections. J Thorac Dis. 2014;6(3):210-220.

4

Tao H, Zheng W. Non-Tuberculous Mycobacterial Infections of the Skin and Soft Tissue in a Chinese Population: A Retrospective Analysis of 15 Cases. Infect Drug Resist. 2025;18:5139-5147.

10.2147/IDR.S54014741048206PMC12495918
5

Krantz AM, Varnam M, Fernandez C. Nontuberculous Mycobacteria Lymphadenitis: A Case Report. Cureus. 2016;8(10):e846.

10.7759/cureus.84627909634PMC5120969
6

Kumar K, Ponnuswamy A, Capstick TG, Chen C, McCabe D, Hurst R, et al. Non-tuberculous mycobacterial pulmonary disease (NTM-PD): Epidemiology, diagnosis and multidisciplinary management. Clin Med (Lond). 2024;24(1):100017.

10.1016/j.clinme.2024.10001738387207PMC11024839
7

Burzynska W, Fol M, Druszczynska M. Growing Challenges of Lung Infections with Non-tuberculous Mycobacteria in Immunocompromised Patients: Epidemiology and Treatment. Arch Immunol Ther Exp (Warsz). 2025;73(1).

10.2478/aite-2025-0005
8

Yadav P, Meena DS, Kumar D, John N, Kaur N, Kombade S, et al. Clinical spectrum of extrapulmonary non-tuberculous mycobacterial disease in immunocompetent patients: a case series. Germs. 2024;14(2):197-203.

10.18683/germs.2024.143139493744PMC11527488
9

Kim JY, Kwak N, Yim JJ. The Rise in Prevalence and Related Costs of Nontuberculous Mycobacterial Diseases in South Korea, 2010-2021. Open Forum Infect Dis. 2022;9(12):ofac649.

10.1093/ofid/ofac64936570964PMC9772866
10

Koh WJ, Chang B, Jeong BH, Jeon K, Kim SY, Lee NY, et al. Increasing Recovery of Nontuberculous Mycobacteria from Respiratory Specimens over a 10-Year Period in a Tertiary Referral Hospital in South Korea. Tuberc Respir Dis (Seoul). 2013;75(5):199-204.

10.4046/trd.2013.75.5.19924348667PMC3861375
11

Lee YM, Kim MJ, Kim YJ. Increasing Trend of Nontuberculous Mycobacteria Isolation in a Referral Clinical Laboratory in South Korea. Medicina (Kaunas). 2021;57(7):720.

10.3390/medicina5707072034357001PMC8306165
12

Conyers LE, Saunders BM. Treatment for non-tuberculous mycobacteria: challenges and prospects. Front Microbiol. 2024;15:1394220.

10.3389/fmicb.2024.139422038887711PMC11180805
13

Poonawala H, Davis K, Kenny ME, Alivisatos A, Van N, Washington T, et al. Antibiotic dose-response curves can measure antibiotic activity against Mycobacterium abscessus and Mycobacterium peregrinum. Antimicrob Agents Chemother. 2026;70(5):e0187625.

10.1128/aac.01876-2541940813PMC13148060
14

Melbouci D, Haidar Ahmad A, Decker P. Neutrophil extracellular traps (NET): not only antimicrobial but also modulators of innate and adaptive immunities in inflammatory autoimmune diseases. RMD Open. 2023;9(3): e003104.

10.1136/rmdopen-2023-00310437562857PMC10423839
15

Torfs K, Vermeersch G, Gouwy M, Devos T, Proost P, Struyf S. Neutrophils as critical orchestrators of chronic inflammation. Cell Mol Immunol. 2026;23(2):123-149.

10.1038/s41423-025-01380-w41530536PMC12858905
16

Calo CJ, Radke M, Patil T, Hind LE. Regulation of neutrophil function by the extracellular matrix. Biochem Soc Trans. 2025;53(5):1325-1336.

10.1042/BST2025302041104438PMC12687429
17

Goncalves AS, Appelberg R. The involvement of the chemokine receptor CXCR2 in neutrophil recruitment in LPS-induced inflammation and in Mycobacterium avium infection. Scand J Immunol. 2002;55(6):585-591.

10.1046/j.1365-3083.2002.01097.x
18

Alkarni M, Lipman M, Lowe DM. The roles of neutrophils in non-tuberculous mycobacterial pulmonary disease. Ann Clin Microbiol Antimicrob. 2023;22(1):14.

10.1186/s12941-023-00562-636800956PMC9938600
19

Zhang L, Lin TY, Liu WT, Ling F. Toward Characterizing Environmental Sources of Non-tuberculous Mycobacteria (NTM) at the Species Level: A Tutorial Review of NTM Phylogeny and Phylogenetic Classification. ACS Environ Au. 2024;4(3):127-141.

10.1021/acsenvironau.3c0007438765059PMC11100324
20

Maleki MR, Moaddab SR. The growing impact of nontuberculous mycobacteria: A multidisciplinary review of ecology, pathogenesis, diagnosis, and treatment. Infect Med (Beijing). 2025;4(3):100203.

10.1016/j.imj.2025.10020341020072PMC12464587
21

Lee MY, Lee T, Kim MH, Byun SS, Ko MK, Hong JM, et al. Regional differences of nontuberculous mycobacteria species in Ulsan, Korea. J Thorac Dis. 2014;6(7):965-970.

22

Chen SW, Chen TH, Huang WH, Hou CC, Lin CJ, Chang YF, et al. Antimicrobial resistance of rapidly growing mycobacteria isolated from companion animals in Taiwan. Microbiol Spectr. 2025;13(7):e0307424.

10.1128/spectrum.03074-2440387379PMC12211053
23

Ghazi Chaki SS, Pirsoltan SB, Beig M, Navidifar T, Parvizi E, Mofid M, et al. Global trends in the proportion of macrolide-resistant Mycobacterium Species: A systematic review and meta-analysis. PLoS One. 2025;20(11):e0333521.

10.1371/journal.pone.033352141202089PMC12594324
24

Abbas M, Khan MT, Iqbal Z, Ali A, Eddine BT, Yousaf N, et al. Sources, transmission and hospital-associated outbreaks of nontuberculous mycobacteria: a review. Future Microbiol. 2024;19(8):715-740.

10.2217/fmb-2023-027939015998PMC11259073
25

Honda JR. Environmental Sources and Transmission of Nontuberculous Mycobacteria. Clin Chest Med. 2023; 44(4):661-674.

10.1016/j.ccm.2023.07.001
26

Loebinger MR, Quint JK, van der Laan R, Obradovic M, Chawla R, Kishore A, et al. Risk Factors for Nontuberculous Mycobacterial Pulmonary Disease: A Systematic Literature Review and Meta-Analysis. Chest. 2023;164(5):1115-1124.

10.1016/j.chest.2023.06.014
27

Namkoong H, Holland SM. Host Susceptibility to Nontuberculous Mycobacterial Pulmonary Disease. Clin Chest Med. 2023;44(4):723-730.

10.1016/j.ccm.2023.07.00237890911PMC10614071
28

Li J, Zeng P, Mu X, Cai C. Clinical Characteristics and Risk Factors Analysis of Nontuberculous Mycobacterial Pulmonary Disease Complicated with Bronchiectasis. Infect Drug Resist. 2026;19:483326.

10.2147/IDR.S48332641768378PMC12947649
29

Gu Y, Nie W, Huang H, Yu X. Non-tuberculous mycobacterial disease: progress and advances in the development of novel candidate and repurposed drugs. Front Cell Infect Microbiol. 2023;13:1243457.

10.3389/fcimb.2023.124345737850054PMC10577331
30

Guglielmi VE, Cummings JE, Whittel NJ, Langland EA, Slayden RA. NTM-host matched infection models for the classification of drug efficacy against rapid and slow growing nontuberculous mycobacteria species. Sci Rep. 2026;16(1): 8762.

10.1038/s41598-026-40034-341688549PMC12982489
31

Gross JE, Jones MC, Buige A, Prevots DR, Kasperbauer S. Pulmonary nontuberculous mycobacterial infections among women with cystic fibrosis and non-cystic fibrosis bronchiectasis. Ther Adv Respir Dis. 2025;19:17534666251323181.

10.1177/1753466625132318140071337PMC11898043
32

Lee H, Jang JG, Kim Y, Min KH, Ahn JH, Yoo KH, et al. Prevalence of Chronic Obstructive Pulmonary Disease in Patients with Nontuberculous Mycobacterial Pulmonary Disease: A Systemic Review and Meta-Analysis. J Pers Med. 2024;14(11): 1089.

10.3390/jpm1411108939590581PMC11595912
33

Chai J, Han X, Mei Q, Liu T, Walline JH, Xu J, et al. Clinical Characteristics and Mortality of Non-tuberculous Mycobacterial Infection in Immunocompromised vs. Immunocompetent Hosts. Front Med (Lausanne). 2022;9:884446.

10.3389/fmed.2022.88444635665363PMC9159854
34

Henkle E, Winthrop KL. Nontuberculous mycobacteria infections in I mmunosuppressed hosts. Clin Chest Med. 2015;36(1):91-99.

10.1016/j.ccm.2014.11.00225676522PMC4710582
35

Park DW, Kim YJ, Sung YK, Chung SJ, Yeo Y, Park TS, et al. TNF inhibitors increase the risk of nontuberculous mycobacteria in patients with seropositive rheumatoid arthritis in a mycobacterium tuberculosis endemic area. Sci Rep. 2022;12(1):4003.

10.1038/s41598-022-07968-w35256729PMC8901670
36

Marras T, Zahng Q, Mirsaeidi M, Vinnard C, Hamilton K, Adjemian J, et al. 122. All-Cause Mortality Increased With Nontuberculous Mycobacterial Lung Disease in US Medicare. Open Forum Infect Dis. 2018;5(Suppl 1):S7.

10.1093/ofid/ofy209.013PMC6252519
37

Kang JY, Han K, Kim MK. Severity of underweight affects the development of nontuberculous mycobacterial pulmonary disease; a nationwide longitudinal study. Sci Rep. 2022;12(1):17180.

10.1038/s41598-022-21511-x36229470PMC9558037
38

Chung E, Park Y, Kim SY, Park MS, Kim YS, Lee HJ, et al. Myosteatosis as a prognostic factor of Mycobacterium avium complex pulmonary disease. Sci Rep. 2023;13(1):13680.

10.1038/s41598-023-40984-y37608053PMC10444847
39

Lore NI, Yamasaki S, Simmonds RE, Jo EK. Editorial: Host-pathogen interactions in nontuberculous mycobacterial infections. Front Immunol. 2023;14:1201159.

10.3389/fimmu.2023.120115937304297PMC10250959
40

Wang Z, Sun X, Lin Y, Fu Y, Yi Z. Stealth in non-tuberculous mycobacteria: clever challengers to the immune system. Microbiol Res. 2025;292:128039.

10.1016/j.micres.2024.128039
41

Nieto Ramirez LM, Mehaffy C, Dobos KM. Systematic review of innate immune responses against Mycobacterium tuberculosis complex infection in animal models. Front Immunol. 2025;15:1467016.

10.3389/fimmu.2024.146701639949719PMC11821578
42

Cruz-Aguilar M, Castillo-Rodal AI, Arredondo-Hernandez R, Lopez-Vidal Y. Non-tuberculous mycobacteria immunopathogenesis: Closer than they appear. a prime of innate immunity trade-off and NTM ways into virulence. Scand J Immunol. 2021;94(2):e13035.

10.1111/sji.1303533655533PMC9285547
43

Koyuncu D, Niazi MKK, Tavolara T, Abeijon C, Ginese ML, Liao Y, et al. CXCL1: A new diagnostic biomarker for human tuberculosis discovered using Diversity Outbred mice. PLoS Pathog. 2021;17(8):e1009773.

10.1371/journal.ppat.100977334403447PMC8423361
44

Lyadova IV. Neutrophils in Tuberculosis: Heterogeneity Shapes the Way? Mediators Inflamm. 2017;2017:8619307.

10.1155/2017/861930728626346PMC5463159
45

Nouailles G, Dorhoi A, Koch M, Zerrahn J, Weiner J 3rd, Fae KC, et al. CXCL5-secreting pulmonary epithelial cells drive destructive neutrophilic inflammation in tuberculosis. J Clin Invest. 2014;124(3):1268-1282.

10.1172/JCI7203024509076PMC3934185
46

Torraca V, Otto NA, Tavakoli-Tameh A, Meijer AH. The inflammatory chemokine Cxcl18b exerts neutrophil-specific chemotaxis via the promiscuous chemokine receptor Cxcr2 in zebrafish. Dev Comp Immunol. 2017;67:57-65.

10.1016/j.dci.2016.10.014
47

Silva MT, Silva MN, Appelberg R. Neutrophil-macrophage cooperation in the host defence against mycobacterial infections. Microb Pathog. 1989;6(5):369-380.

10.1016/0882-4010(89)90079-X
48

Gierlikowska B, Stachura A, Gierlikowski W, Demkow U. Phagocytosis, Degranulation and Extracellular Traps Release by Neutrophils-The Current Knowledge, Pharmacological Modulation and Future Prospects. Front Pharmacol. 2021;12:666732.

10.3389/fphar.2021.66673234017259PMC8129565
49

Liao YX, Xia L, Liu P, Li XH, Liu LP, Xu L, et al. Five CGD-Linked CYBB Mutations in Chinese Patients: Insights Into Predicting IFN-gamma Treatment Efficacy. J Clin Immunol. 2025;45(1):131.

10.1007/s10875-025-01926-741026270PMC12484266
50

Fine N, Tasevski N, McCulloch CA, Tenenbaum HC, Glogauer M. The Neutrophil: Constant Defender and First Responder. Front Immunol. 2020;11:571085.

10.3389/fimmu.2020.57108533072112PMC7541934
51

Lowe DM, Redford PS, Wilkinson RJ, O’Garra A, Martineau AR. Neutrophils in tuberculosis: friend or foe? Trends Immunol. 2012;33(1):14-25.

10.1016/j.it.2011.10.003
52

Appelberg R, Castro AG, Gomes S, Pedrosa J, Silva MT. Susceptibility of beige mice to Mycobacterium avium: role of neutrophils. Infect Immun. 1995;63(9):3381-3387.

10.1128/iai.63.9.3381-3387.19957642266PMC173465
53

Saunders BM, Cheers C. Intranasal infection of beige mice with Mycobacterium avium complex: role of neutrophils and natural killer cells. Infect Immun. 1996;64(10):4236-4241.

10.1128/iai.64.10.4236-4241.19968926094PMC174362
54

Feng CG, Scanga CA, Collazo-Custodio CM, Cheever AW, Hieny S, Caspar P, et al. Mice lacking myeloid differentiation factor 88 display profound defects in host resistance and immune responses to Mycobacterium avium infection not exhibited by Toll-like receptor 2 (TLR2)- and TLR4-deficient animals. J Immunol. 2003;171(9):4758-4764.

10.4049/jimmunol.171.9.4758
55

Petrofsky M, Bermudez LE. Neutrophils from Mycobacterium avium-infected mice produce TNF-alpha, IL-12, and IL-1 beta and have a putative role in early host response. Clin Immunol. 1999;91(3):354-358.

10.1006/clim.1999.4709
56

Faldt J, Dahlgren C, Ridell M. Difference in neutrophil cytokine production induced by pathogenic and non- pathogenic mycobacteria. APMIS. 2002;110(9):593-600.

10.1034/j.1600-0463.2002.1100901.x
57

Miralda I, Klaes CK, Graham JE, Uriarte SM. Human Neutrophil Granule Exocytosis in Response to Mycobacterium smegmatis. Pathogens. 2020;9(2):123.

10.3390/pathogens902012332075233PMC7169382
58

Tateishi Y, Ozeki Y, Nishiyama A, Miki M, Maekura R, Kida H, et al. Virulence of Mycobacterium intracellulare clinical strains in a mouse model of lung infection - role of neutrophilic inflammation in disease severity. BMC Microbiol. 2023;23(1):94.

10.1186/s12866-023-02831-y37009882PMC10069106
59

Lenhart-Pendergrass PM, Malcolm KC, Wheeler E, Rysavy NM, Poch K, Caceres S, et al. Deficient Complement Opsonization Impairs Mycobacterium avium Killing by Neutrophils in Cystic Fibrosis. Microbiol Spectr. 2023;11(1): e0327922.

10.1128/spectrum.03279-2236651756PMC9927418
60

Caverly LJ, Caceres SM, Fratelli C, Happoldt C, Kidwell KM, Malcolm KC, et al. Mycobacterium abscessus morphotype comparison in a murine model. PLoS One. 2015;10(2):e0117657.

10.1371/journal.pone.011765725675351PMC4326282
61

Kondratieva E, Logunova N, Majorov K, Averbakh M, Apt A. Host genetics in granuloma formation: human-like lung pathology in mice with reciprocal genetic susceptibility to M. tuberculosis and M. avium. PLoS One. 2010;5(5):e10515.

10.1371/journal.pone.001051520463893PMC2865535
62

Poli V, Zanoni I. Neutrophil intrinsic and extrinsic regulation of NETosis in health and disease. Trends Microbiol. 2023;31(3):280-293.

10.1016/j.tim.2022.10.00236344311PMC9974585
63

Nasir MH, Rehman AU, Yusoff MB, Ishaq M, Alkhateeb A, Shkodina AD, et al. Neutrophil extracellular traps (NETs) extrusion in infection and diseases: A hallway for diagnosis and prognosis. Eur J Pharmacol. 2026;1021:178822.

10.1016/j.ejphar.2026.178822
64

Xiong J, Xue J, Zhou H, Qi W, Zhu H. The crosstalk of neutrophil extracellular trap-inflammasome and their roles in disease progression. Mol Aspects Med. 2025;106:101419.

10.1016/j.mam.2025.101419
65

Chowdhury CS, Kinsella RL, McNehlan ME, Naik SK, Lane DS, Talukdar P, et al. Type I IFN-mediated NET release promotes Mycobacterium tuberculosis replication and is associated with granuloma caseation. Cell Host Microbe. 2024;32(12):2092-111. e7.

10.1016/j.chom.2024.11.00839637864PMC11637906
66

Liu D, Mai D, Jahn AN, Murray TA, Aitchison JD, Gern BH, et al. APOE protects against severe infection with Mycobacterium tuberculosis by restraining production of neutrophil extracellular traps. PLoS Pathog. 2025;21(6):e1013267.

10.1371/journal.ppat.101326740523023PMC12201663
67

Moreira-Teixeira L, Stimpson PJ, Stavropoulos E, Hadebe S, Chakravarty P, Ioannou M, et al. Type I IFN exacerbates disease in tuberculosis-susceptible mice by inducing neutrophil-mediated lung inflammation and NETosis. Nat Commun. 2020;11(1):5566.

10.1038/s41467-020-19412-633149141PMC7643080
68

Nakamura K, Nakayama H, Sasaki S, Takahashi K, Iwabuchi K. Mycobacterium avium-intracellulare complex promote release of pro-inflammatory enzymes matrix metalloproteinases by inducing neutrophil extracellular trap formation. Sci Rep. 2022;12(1):5181.

10.1038/s41598-022-09017-y35410994PMC9001666
69

Singh S, Darawshy F, Erlandson K, Narayana JK, Li Q, Li Y, et al. Lower Airway Dysbiosis in nontuberculous mycobacteria-positive Bronchiectasis is Associated with neutrophil extracellular trap-Predominant Severe Phenotypes. Am J Respir Crit Care Med. 2026;212(5):936-951.

10.1093/ajrccm/aamag01541738242PMC13160944
70

Jeon SM, Lee YJ, Lee SH, Kim SI, Lee B, Roh T, et al. ATG7 in innate immune cells is required for host defense against nontuberculous mycobacterial pulmonary infections. Nat Commun. 2025;16(1):6966.

10.1038/s41467-025-61791-140730835PMC12307950
71

Moreira-Teixeira L, Mayer-Barber K, Sher A, O’Garra A. Type I interferons in tuberculosis: Foe and occasionally friend. J Exp Med. 2018;215(5):1273-1285.

10.1084/jem.2018032529666166PMC5940272
72

Muefong CN, Sutherland JS. Neutrophils in Tuberculosis-Associated Inflammation and Lung Pathology. Front Immunol. 2020;11:962.

10.3389/fimmu.2020.0096232536917PMC7266980
73

Bermudez LE, Petrofsky M, Stevens P. Treatment with recombinant granulocyte colony-stimulating factor (Filgrastin) stimulates neutrophils and tissue macrophages and induces an effective non-specific response against Mycobacterium avium in mice. Immunology. 1998;94(3):297-303.

10.1046/j.1365-2567.1998.00529.x9767410PMC1364245
74

Yamamoto K, Torigoe S, Tsujimura Y, Asaka MN, Okumura K, Ato M. In vivo imaging identified efficient antimicrobial treatment against Mycobacterium marinum infection in mouse footpads. Sci Rep. 2024;14(1):24343.

10.1038/s41598-024-75207-539420066PMC11487254
75

Lienard J, Munke K, Wulff L, Da Silva C, Vandamme J, Laschanzky K, et al. Intragranuloma Accumulation and Inflammatory Differentiation of Neutrophils Underlie Mycobacterial ESX-1-Dependent Immunopathology. mBio. 2023;14(2):e0276422.

10.1128/mbio.02764-2237017530PMC10127687
76

Cowman SA, Jacob J, Hansell DM, Kelleher P, Wilson R, Cookson WOC, et al. Whole-Blood Gene Expression in Pulmonary Nontuberculous Mycobacterial Infection. Am J Respir Cell Mol Biol. 2018;58(4):510-518.

10.1165/rcmb.2017-0230OC29206475PMC5894497
77

Zhang XY, Li Y, Zhao J, Deng FQ, Tang XH, Li JF, et al. Pathological and immune features of non-tuberculous mycobacteria and Mycobacterium tuberculosis cutaneous/mucosa infections of fifty-four biopsies. Front Cell Infect Microbiol. 2025;15:1664902.

10.3389/fcimb.2025.166490241189710PMC12580264
78

Hashimoto K, Abe Y, Fukushima K, Niitsu T, Komukai S, Miyamoto S, et al. Epidemiology of bronchiectasis at a single center in Japan: a retrospective cohort study. BMC Pulm Med. 2024;24(1):531.

10.1186/s12890-024-03337-7
79

Wang P, Yang GL, He YF, Shen YH, Hao XH, Liu HP, et al. Single-cell transcriptomics of blood identified IFIT1(+) neutrophil subcluster expansion in NTM-PD patients. Int Immunopharmacol. 2024;137:112412.

10.1016/j.intimp.2024.112412
80

Furuuchi K, Hijikata M, Seto S, Miyabayashi A, Wakabayashi K, Nakagawa T, et al. Gene expression profiling of airway epithelium in Mycobacterium avium complex lung disease. ERJ Open Res. 2025;11(5).

10.1183/23120541.00011-2025
81

Oda N, Matsui H, Oya N, Suzuki T, Hazue R, Rokutanda R. Pulmonary non-t uberculous mycobacteria disease and anti-neutrophil cytoplasmic antibody positivity: a retrospective analysis of long-term clinical outcomes including vasculitis onset. Clin Exp Rheumatol. 2026;44(4):678-686.

10.55563/clinexprheumatol/2kjm03
82

Chai J, Zhang S, Ma C, Mei Q, Liu T, Liu J, et al. Clinical analysis and risk factors associated with poor prognosis in nontuberculous mycobacterial infection. Virulence. 2025;16(1):2459313.

10.1080/21505594.2025.2459313
83

Chen CY, Sheng WH, Lai CC, Liao CH, Huang YT, Tsay W, et al. Mycobacterial infections in adult patients with hematological malignancy. Eur J Clin Microbiol Infect Dis. 2012;31(6):1059-1066.

10.1007/s10096-011-1407-7
Information
  • Publisher :The Korean Society for Microbiology and The Korean Society of Virology
  • Publisher(Ko) :대한미생물학회‧대한바이러스학회
  • Journal Title :JOURNAL OF BACTERIOLOGY AND VIROLOGY
  • Volume : 56
  • No :2
  • Pages :112-126
  • Received Date : 2026-06-30
  • Revised Date : 2026-07-09
  • Accepted Date : 2026-07-10
  • DOI :https://doi.org/10.4167/jbv.2026.56.2.112
Journal Informaiton JOURNAL OF BACTERIOLOGY AND VIROLOGY JOURNAL OF BACTERIOLOGY AND VIROLOGY
  • NRF
  • 임플란트학회 전용 배너
  • KOFST
  • crossref crossmark
  • crossref cited-by
  • crossref funder-registry
  • crosscheck
  • orcid
  • open access
  • ccl
Journal Informaiton Journal Informaiton - close